Supernus Pharmaceuticals, Inc.
SUPN· Nasdaq
SUPNSupernus Pharmaceuticals, Inc.
Filed Mar 8, 2021 · 10-K · 67 days after period end · 0001356576-21-000028
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $143.56M | $100.45M | $115.93M | $88.44M |
| Net Income | $30.77M | $33.13M | $25.89M | $13.66M |
| EPS Diluted | — | $0.62 | $0.48 | $0.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Mar 8, 2021 · 67 d after period end
